论文部分内容阅读
目的:探讨联合使用吉西他滨和奥沙利铂(Gemox)序贯放疗治疗中晚期非小细胞肺癌的临床效果及安全性。方法:在为2007年4月至2009年4月我院收治的90例中晚期非小细胞肺癌患者进行治疗的过程中,采用随机数字表法将其分为两组,为45例对照组患者使用吉西他滨和顺铂进行治疗,具体方法为:吉西他滨1g/m2,d1、d8静脉滴注;顺铂250mg/m2,d1静脉滴注。为45例Gemox组患者联合使用吉西他滨和奥沙利铂进行治疗,方法为:吉西他滨1g/m2,d1、d8静脉滴注;奥沙利铂150mg/m2,d1静脉滴注。在为两组患者进行化疗6周后为其进行总剂量为65-70Gy的放疗,之后再进行12周的化疗。比较两组患者治疗的总有效率、1年及2年生存率、中位生存时间及发生不良反应的几率等。结果:对照组患者的治疗总有效率为62.2%,Gemox组患者的治疗总有效率为64.4%。将两组患者治疗的总有效率相比较,无显著差异(p>0.05)。将两组患者的1年及2年生存率相比较,无显著差异(p>0.05)。将两组患者的中位生存时间相比较,无显著差异(p>0.05)。Gemox组患者在治疗期间发生恶心呕吐、粒细胞减少、血小板减少及周围神经损害等不良反应的几率明显低于对照组患者,差异显著(p<0.05)。结论:联合使用吉西他滨和奥沙利铂(Gemox)序贯放疗治疗中晚期非小细胞肺癌的临床效果确切,可有效改善患者的临床症状,延缓其病情进展,延长其生存时间,改善其生活质量,而且不良反应较少。
Objective: To investigate the clinical efficacy and safety of combination gemcitabine and Gemox sequential radiotherapy in the treatment of advanced non-small cell lung cancer. Methods: During the treatment of 90 patients with advanced non-small cell lung cancer who were admitted to our hospital from April 2007 to April 2009, they were divided into two groups according to the random number table method: 45 patients in the control group The use of gemcitabine and cisplatin for treatment, specific methods: gemcitabine 1g / m2, d1, d8 intravenous infusion; cisplatin 250mg / m2, d1 intravenous drip. 45 gemox patients were treated with gemcitabine and oxaliplatin for gemcitabine 1g / m2, d1, d8 intravenous infusion; oxaliplatin 150mg / m2, d1 intravenous infusion. After 6 weeks of chemotherapy for both groups, they were given a total dose of 65-70 Gy, followed by 12 weeks of chemotherapy. The total effective rate, the 1-year and 2-year survival rates, the median survival time and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate was 62.2% in the control group and 64.4% in the Gemox group. There was no significant difference in the total effective rate between the two groups (p> 0.05). Comparing the 1-year and 2-year survival rates of the two groups, there was no significant difference (p> 0.05). There was no significant difference between the two groups in the median survival time (p> 0.05). The incidence of nausea and vomiting, neutropenia, thrombocytopenia and peripheral nerve damage in Gemox group was significantly lower than that in control group (p <0.05). Conclusions: The combination of gemcitabine and Gemox sequential radiotherapy in the treatment of advanced non-small cell lung cancer has the exact clinical effect, which can effectively improve the clinical symptoms, delay the progression of the disease, prolong the survival time and improve the quality of life , And less adverse reactions.